OBJECTIVES: We sought to define the cardiometabolic phenotype associated with rs5068, a genetic variant of the atrial natriuretic peptide (ANP) gene. BACKGROUND: The ANP and B-type natriuretic peptide play an important role in cardiorenal homeostasis but also exert metabolic actions. METHODS: We genotyped 1,608 randomly selected residents from Olmsted County, Minnesota. Subjects were well-characterized. RESULTS: Genotype frequencies were: AA 89.9%, AG 9.7%, and GG 0.4%; all subsequent analyses were AA versus AG+GG. The G allele was associated with increased plasma levels of N-terminal pro-atrial natriuretic peptide (p = 0.002), after adjustment for age and sex. The minor allele was also associated with lower body mass index (BMI) (p = 0.006), prevalence of obesity (p = 0.002), waist circumference (p = 0.021), lower levels of C-reactive protein (p = 0.027), and higher values of high-density lipoprotein cholesterol (p = 0.019). The AG+GG group had a lower systolic blood pressure (p = 0.011) and lower prevalence of myocardial infarction (p = 0.042). The minor allele was associated with a lower prevalence of metabolic syndrome (p = 0.025). The associations between the G allele and high-density lipoprotein cholesterol, C-reactive protein values, myocardial infarction, and metabolic syndrome were not significant, after adjusting for BMI; the associations with systolic blood pressure, BMI, obesity, and waist circumference remained significant even after adjusting for N-terminal pro-atrial natriuretic peptide. CONCLUSIONS: In a random sample of the general U.S. population, the minor allele of rs5068 is associated with a favorable cardiometabolic profile. These findings suggest that rs5068 or genetic loci in linkage disequilibrium might affect susceptibility for cardiometabolic diseases and support the possible protective role of natriuretic peptides by their favorable effects on metabolic function. Replication studies are needed to confirm our findings.
OBJECTIVES: We sought to define the cardiometabolic phenotype associated with rs5068, a genetic variant of the atrial natriuretic peptide (ANP) gene. BACKGROUND: The ANP and B-type natriuretic peptide play an important role in cardiorenal homeostasis but also exert metabolic actions. METHODS: We genotyped 1,608 randomly selected residents from Olmsted County, Minnesota. Subjects were well-characterized. RESULTS: Genotype frequencies were: AA 89.9%, AG 9.7%, and GG 0.4%; all subsequent analyses were AA versus AG+GG. The G allele was associated with increased plasma levels of N-terminal pro-atrial natriuretic peptide (p = 0.002), after adjustment for age and sex. The minor allele was also associated with lower body mass index (BMI) (p = 0.006), prevalence of obesity (p = 0.002), waist circumference (p = 0.021), lower levels of C-reactive protein (p = 0.027), and higher values of high-density lipoprotein cholesterol (p = 0.019). The AG+GG group had a lower systolic blood pressure (p = 0.011) and lower prevalence of myocardial infarction (p = 0.042). The minor allele was associated with a lower prevalence of metabolic syndrome (p = 0.025). The associations between the G allele and high-density lipoprotein cholesterol, C-reactive protein values, myocardial infarction, and metabolic syndrome were not significant, after adjusting for BMI; the associations with systolic blood pressure, BMI, obesity, and waist circumference remained significant even after adjusting for N-terminal pro-atrial natriuretic peptide. CONCLUSIONS: In a random sample of the general U.S. population, the minor allele of rs5068 is associated with a favorable cardiometabolic profile. These findings suggest that rs5068 or genetic loci in linkage disequilibrium might affect susceptibility for cardiometabolic diseases and support the possible protective role of natriuretic peptides by their favorable effects on metabolic function. Replication studies are needed to confirm our findings.
Authors: M Nemer; M Chamberland; D Sirois; S Argentin; J Drouin; R A Dixon; R A Zivin; J H Condra Journal: Nature Date: 1984 Dec 13-19 Impact factor: 49.962
Authors: Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer Journal: JAMA Date: 2003-01-08 Impact factor: 56.272
Authors: J C Burnett; P C Kao; D C Hu; D W Heser; D Heublein; J P Granger; T J Opgenorth; G S Reeder Journal: Science Date: 1986-03-07 Impact factor: 47.728
Authors: Allison M Pritchett; Steven J Jacobsen; Douglas W Mahoney; Richard J Rodeheffer; Kent R Bailey; Margaret M Redfield Journal: J Am Coll Cardiol Date: 2003-03-19 Impact factor: 24.094
Authors: D E Uehlinger; P Weidmann; M P Gnädinger; L Hasler; C Bachmann; S Shaw; B Hellmüller; R E Lang Journal: J Cardiovasc Pharmacol Date: 1986 Nov-Dec Impact factor: 3.105
Authors: Valentina Cannone; Simona Barlera; Silvana Pileggi; Serge Masson; Maria Grazia Franzosi; Roberto Latini; Cesare Scardulla; Francesco Clemenza; Aldo P Maggioni; Gian Luigi Nicolosi; Luigi Tavazzi; John C Burnett Journal: Int J Cardiol Date: 2014-08-04 Impact factor: 4.164
Authors: Deepak K Gupta; Lori B Daniels; Susan Cheng; Christopher R deFilippi; Michael H Criqui; Alan S Maisel; Joao A Lima; Hossein Bahrami; Philip Greenland; Mary Cushman; Russell Tracy; David Siscovick; Alain G Bertoni; Valentina Cannone; John C Burnett; John Jeffrey Carr; Thomas J Wang Journal: Am J Cardiol Date: 2017-06-30 Impact factor: 2.778
Authors: Yang Chen; Jacob J Schaefer; Seethalakshmi R Iyer; Gerald E Harders; Shuchong Pan; S Jeson Sangaralingham; Horng H Chen; Margaret M Redfield; John C Burnett Journal: Am J Physiol Regul Integr Comp Physiol Date: 2020-02-05 Impact factor: 3.619
Authors: Valentina Cannone; Brenda K Huntley; Timothy M Olson; Denise M Heublein; Christopher G Scott; Kent R Bailey; Margaret M Redfield; Richard J Rodeheffer; John C Burnett Journal: Hypertension Date: 2013-09-16 Impact factor: 10.190
Authors: Brendan M Everett; Nancy R Cook; Daniel I Chasman; Maria C Magnone; Maria Bobadilla; Nader Rifai; Paul M Ridker; Aruna D Pradhan Journal: Clin Chem Date: 2013-01-03 Impact factor: 8.327